guillain-barré syndrome after receiving the first dose of oxford–astrazeneca sars-cov-2 vaccine

Safety monitoring of covid-19 vaccination is paramount of importance. there are limited reports of guillain-barré syndrome (gbs) associated with the covid-19 vaccination. the present study reported a case of gbs following the first dose of the oxford-astrazeneca sars-cov-2 vaccine. a 32-year-old man presented a history of progressive descending weakness and autonomic features within a month after receiving the oxford-astrazeneca sars-cov-2 vaccine. the neurological examination was consistent with acute polyneuropathy. the para-clinical investigations were in favor of acute demyelinating polyneuropathy. the patient was diagnosed with gbs, and ivig was initiated as an acute treatment, which led to significant clinical recovery. we reported a case of gbs after receiving the oxford-astrazeneca vaccine. however, our findings dose not conclude a causal association between gbs and covid-19 vaccination.